Prognostic impact of concurrent radiographic progression at PSA-defined transition to castration resistance in de novo metastatic castration-sensitive prostate cancer
Background Radiographic progression (rPD) at castration-resistant prostate cancer (CRPC) diagnosis remains poorly characterized in real-world settings. We assessed its prognostic impact and the clinical features of patients with rPD in real-world de novo metastatic castration-sensitive prostate cancer (mCSPC). Methods We retrospectively analyzed 330 patients with de novo mCSPC who progressed to CRPC from two multi-institutional cohorts: a conventional androgen deprivation therapy or combined androgen blockade (ADT/CAB) cohort ( n = 272) and an upfront intensification cohort ( n = 58). At CRPC diagnosis, patients were categorized as having prostate-specific antigen (PSA)-only progression or PSA + rPD. Post-CRPC overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards models, while rPD-associated characteristics were examined using logistic regression. Results Across both cohorts, patients with PSA + rPD had significantly shorter post-CRPC OS than those with PSA-only progression (ADT/CAB: 21 vs. 44 months, P < 0.001; upfront: 14 vs. 24 months, P = 0.008). Univariate Cox regression confirmed the adverse prognostic impact of rPD (hazard ratios 2.25 [95% CI 1.53–3.29] and 2.49 [95% CI 1.22–5.07]). Lower baseline PSA was significantly associated with rPD in the upfront cohort (odds ratio [OR] 0.30, 95% CI 0.12–0.75, P = 0.010), with a non-significant trend in the ADT/CAB cohort (OR 0.71, 95% CI 0.47–1.06, P = 0.092). Conclusion Radiographic progression at CRPC transition predicts poor post-CRPC survival in real-world mCSPC patients, regardless of initial treatment. Lower baseline PSA may identify patients at increased risk of rPD, supporting careful radiographic monitoring at CRPC transition.
Authors
- Koji Yoshimura (ORCID: https://orcid.org/0000-0001-6342-7691)
- Noboru Shibasaki
- Hiroaki Kawanishi (ORCID: https://orcid.org/0009-0004-0955-5683)
- Takeru Fujimoto (ORCID: https://orcid.org/0000-0002-1576-2927)
- Masashi Kubota (ORCID: https://orcid.org/0000-0002-6978-6932)
- Yu Miyazaki (ORCID: https://orcid.org/0000-0003-0949-4812)
- Ryoma Kurahashi (ORCID: https://orcid.org/0000-0001-6972-8065)
- Yoshiyuki Nagumo (ORCID: https://orcid.org/0000-0003-0332-4791)
- Kei Mizuno (ORCID: https://orcid.org/0000-0002-1273-5288)
- Kimihiko Masui (ORCID: https://orcid.org/0000-0002-7841-1104)
- Shusuke Akamatsu (ORCID: https://orcid.org/0000-0002-1394-7506)
- Takanari Kambe (ORCID: https://orcid.org/0000-0002-2913-7364)
- Hiroshi Fujiwara (ORCID: https://orcid.org/0000-0002-9380-9778)
- Takayuki Goto (ORCID: https://orcid.org/0000-0001-6537-3068)
- Norihiko Masuda (ORCID: https://orcid.org/0000-0002-3988-6246)
- Toshifumi Takahashi
- Takashi Kobayashi (ORCID: https://orcid.org/0000-0003-1069-2816)
- Takuro Miyagawa
- Yuki Makino
- Yuki Kita
- Takayuki Sumiyoshi
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1007/s10147-026-03239-0
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00